Clinical trial
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary…
NCT00035100 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00035100 |
|---|---|
| Title | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
| Official title | An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms |
| Intervention type | Drug |
| Interventions | epothilone b |
| Enrollment | 54 |
| Start date | Sep 1, 2001 |
| Primary completion | Jun 1, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Apr 16, 2012 |
| Countries | Canada, Netherlands, Slovakia, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: